Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
5CV.DEDay performance
| 5CV.DE | |
|---|---|
| Price | 5.02 |
| Change Pct | -0.79 |
| Change Abs | -0.04 |
| Market Cap | 1.1 billion |
| Eps | -1.47 |
| Pe Ratio | -3.41 |
| Outstanding Shares | 223.9 million |
| Volume | 20290 |
| Avg Volume | 58958 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | DE |
| Announcement Earnings | 2023-03-31 04:00:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
22UA.F
0QF.F
D7G.F
3 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
5CV.DE
Company descriptions
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.